Ellomay Capital Ltd. has filed its Annual Report on Form 20-F for the year ended December 31, 2025, with the SEC. The report includes audited financial statements showing a €1.5 million decrease in project development costs due to a reversal of provisions and a €1.9 million decrease in tax benefits compared to earlier unaudited results. Ellomay continues to develop and operate renewable energy projects across Europe, the USA, and Israel, including solar plants and green gas facilities. The company offers shareholders free access to the full report and audited financials upon request.
Nuvei announced it will acquire Payoneer in an all-cash deal valued at $2.75 billion, offering Payoneer shareholders $7.40 per share. The merger aims to create a global commerce platform supporting businesses in over 190 countries, enhancing payment ...
Eli Lilly announced that its Phase 3 BRUIN CLL-322 trial showed adding Jaypirca (pirtobrutinib) to venetoclax and rituximab significantly improved progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or...
The osteoarthritis market is projected to grow at a moderate CAGR of 3% from 2026 to 2036, driven by an aging population and increasing disease prevalence. Emerging therapies like LEVI-04, ZILOSUL, TissueGene-C, and others are expected to enter the m...
A class action lawsuit has been filed against Nano-X Imaging Ltd. and some of its officers, accusing them of making false and misleading statements about the company's operations and prospects between March 31, 2025, and April 17, 2026. The lawsuit c...
Rhythm Pharmaceuticals reported encouraging six-month Phase 2 trial results for setmelanotide in patients with Prader-Willi syndrome, showing improvements in BMI, body composition, hyperphagia, and behavior. The study involved 18 patients aged 6 to 2...
